Aclaris Therapeutics, Inc.
ACRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001557746
No open-market purchases or sales by Aclaris Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $630.0M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Aclaris Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 98 | 109 | +11 |
| Shares | 87.5M | 92.7M | +5.21M (+6.0%) |
| Value | $217.0M | $143.8M | −$73.2M (−33.7%) |
New holders (23)
Institutions that held Aclaris Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
Sold out (12)
Institutions that held Aclaris Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Janus Henderson Group PLC | 2,799,759 | $6.99M |
| Samsara BioCapital, LLC | 2,385,060 | $5.91M |
| Peapod Lane Capital LLC | 404,452 | $1.00M |
| Exome Asset Management LLC | 389,333 | $965.5K |
| 683 Capital Management, LLC | 217,265 | $538.8K |
| Marquette Asset Management, LLC | 57,911 | $143.6K |
| XTX Topco Ltd | 44,685 | $110.8K |
| Caption Management, LLC | 17,960 | $44.5K |
| Alpine Global Management, LLC | 15,340 | $38.0K |
| Simplex Trading, LLC | 6,695 | $16.0K |
| MAI Capital Management | 1,500 | $3.72K |
| R Squared Ltd | 610 | $1.51K |